I'm with you on this, aidoaido. BLT have said they will have reverted to "normal" reporting of trial results, meaning they won't report on a cohort at half-time. Well that's "normal" for larger biotechs with lots of stuff well advanced, where a single test is not crucial, but for a little biotech like BLT doing its first in-human test, it is just unrealistic. Given how important this is, I think it is simply unacceptable for management not to provide news whenever possible, in order to keep the market fully informed during these crucial early stages.
- Forums
- ASX - By Stock
- BLT
- Ann: App 4E / Full Year Statutory Accounts
Ann: App 4E / Full Year Statutory Accounts, page-64
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online